<?xml version="1.0" encoding="UTF-8"?>
<p id="para520">MDR-1/Pgp is known to be overexpressed in peripheral T-cell lymphoma
 <xref rid="bib7" ref-type="bibr">7</xref>, 
 <xref rid="bib8" ref-type="bibr">8</xref> in the lymphoma cells, residual lymphocytes, and endothelium,
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> and this might account for the reported efficacy of the nucleoside analogue gemcitabine in peripheral T-cell lymphoma, which is not a substrate of the efflux pump.
 <xref rid="bib27" ref-type="bibr">
  <sup>27</sup>
 </xref> The activity of intravenous gemcitabine monotherapy (1200 mg/m
 <sup>2</sup> on days 1, 8, and 15 of a 28-day cycle) was first reported in 1998 in a phase 2 study
 <xref rid="bib9" ref-type="bibr">
  <sup>9</sup>
 </xref> of 13 patients with relapsed or refractory peripheral T-cell lymphoma unspecified or patients with mycosis fungoides with an objective response of 69% and complete response of 8%. Similar efficacy was shown in another study
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref> (objective response 60% and complete response 20%) in a cohort of ten patients with relapsed or refractory T-cell lymphoma using the same dosing schedule. A subsequent study in 2010 confirmed this efficacy (objective response 51%, complete response 23%) in a larger number of relapsed or refractory patients (n=39) with some durable remissions.
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref>
</p>
